Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2025-01-23 Capital/Financing Update
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 233.8KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of shares by Mesoblast Limited to institutional and sophisticated investors under a private placement. It is a regulatory compliance notice about share issuance without disclosure under Part 6D.2 of the Corporations Act. The document does not contain financial statements or detailed financial data but is an announcement related to capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification, so CAP is appropriate.
2025-01-23 English
Ceasing to be a substantial holder 22 pages 1.1MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 filed under the Corporations Act 2001 Section 671B, titled 'Notice of ceasing to be a substantial holder.' It details changes in relevant interests and associations related to substantial shareholdings in Mesoblast Ltd. The form includes transaction details, dates, and signatures of compliance officers. This type of filing is a regulatory notification about changes in significant share ownership levels, specifically ceasing to be a substantial holder. It is not a financial report, earnings release, or management report, but a formal notification of shareholding changes. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory filing about shareholding changes.
2025-01-21 English
Application for quotation of securities - MSB 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from Mesoblast Limited regarding the application for quotation of newly issued securities on the ASX. It references previous announcements (Appendix 3B) related to the securities issuance and provides details about the number and type of securities to be quoted, issue price, and issued capital following quotation. This type of document is a formal application to list new shares on the exchange, which corresponds to announcements about share issues or capital changes. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is over 5,000 characters and contains substantive details about the securities issuance, not merely a notice or link to a report, so it is not a report publication announcement or regulatory filing fallback.
2025-01-21 English
Cleansing Notice 1 page 214.3KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of shares by Mesoblast Limited to institutional and sophisticated investors under a private placement. It is a regulatory announcement about a capital raising event without disclosure under Part 6D.2 of the Corporations Act. The document is short (1471 characters) and serves as a formal notification to the ASX about the share issuance and compliance with relevant sections of the Corporations Act. This fits the category of Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2025-01-21 English
Appendix 3Y for Eric Rose 3 pages 264.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and the value of the transaction. There is no financial performance data, audit information, or report content. Instead, it is a formal notification of a director's personal share transactions. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and contains detailed transaction data, not just an announcement or certification. Therefore, the correct classification is DIRS with high confidence.
2025-01-20 English
Cleansing Notice 1 page 214.0KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of shares by Mesoblast Limited under a private placement. It is a regulatory compliance notice about the share issuance without disclosure under Part 6D.2 of the Corporations Act. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an announcement related to capital raising activities, specifically a private placement of shares. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on the capital issuance notice, not a full report or announcement of voting results or other categories.
2025-01-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.